TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Polarean Imaging ( (GB:POLX) ).
Polarean Imaging has announced that its FDA-cleared XENOVIEW® 3T Chest Coil has passed compatibility testing with Philips’ 3T MRI platforms, marking a significant milestone for the company. This development allows for the integration of Polarean’s technology with Philips MRI systems, enhancing the accessibility of advanced pulmonary imaging and supporting clinical adoption. The milestone positions Polarean to expand its market reach, accelerate adoption, and enhance commercial and clinical value, aligning with its commitment to innovation in pulmonary imaging.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £0.12 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Spark’s Take on GB:POLX Stock
According to Spark, TipRanks’ AI Analyst, GB:POLX is a Neutral.
Polarean Imaging’s overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The revised revenue guidance and market headwinds further weigh on the score. While there are positive developments in sales quotes and international expansion, the risks and financial instability are significant concerns.
To see Spark’s full report on GB:POLX stock, click here.
More about Polarean Imaging
Polarean Imaging is a medical imaging technology company that specializes in pulmonary medicine, offering advanced MRI solutions to visualize lung function. The company has developed the FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, and focuses on non-invasive, radiation-free imaging solutions. Founded in 2012, Polarean operates from Durham, NC, and London, UK, aiming to address the needs of over 500 million patients with chronic respiratory diseases.
YTD Price Performance: -90.57%
Average Trading Volume: 14,924,776
Technical Sentiment Signal: Sell
Current Market Cap: £1.51M
For detailed information about POLX stock, go to TipRanks’ Stock Analysis page.